Search Page

1

Cite

Share

Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden.

Flodmark CE, Lilja K, Woehling H, Järvholm K. Flodmark CE, et al. Among authors: woehling h. Biol Ther. 2013;3(1):35-43. doi: 10.1007/s13554-013-0011-z. Epub 2013 May 28. Biol Ther. 2013. PMID: 24392303 Free PMC article.

Cite

Share

2

Cite

Share

Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.

Gerdes S, Thaçi D, Griffiths CEM, Arenberger P, Poetzl J, Wuerth G, Afonso M, Woehling H. Gerdes S, et al. Among authors: woehling h. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):420-427. doi: 10.1111/jdv.14605. Epub 2017 Nov 2. J Eur Acad Dermatol Venereol. 2018. PMID: 28960486 Free PMC article. Clinical Trial.

Cite

Share

3

Cite

Share

Erratum to: Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System.

Rashid N, Saenger P, Wu YL, Woehling H, Frankel M, Lifshitz F, Muenzberg M, Rapaport R. Rashid N, et al. Among authors: woehling h. Biol Ther. 2014 Dec;4(1-2):81. doi: 10.1007/s13554-014-0020-6. Biol Ther. 2014. PMID: 25407940 Free PMC article. No abstract available.

Cite

Share

4

Cite

Share

Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System.

Rashid N, Saenger P, Wu YL, Woehling H, Frankel M, Lifshitz F, Muenzberg M, Rapaport R. Rashid N, et al. Among authors: woehling h. Biol Ther. 2014 Dec;4(1-2):27-39. doi: 10.1007/s13554-014-0017-1. Epub 2014 Aug 6. Biol Ther. 2014. PMID: 25096555 Free PMC article.

Cite

Share

5

Cite

Share

Two-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age.

Schwarz HP, Walczak M, Birkholz-Walerzak D, Szalecki M, Nanu M, Woehling H, Schuck E. Schwarz HP, et al. Among authors: woehling h. Adv Ther. 2016 Mar;33(3):423-34. doi: 10.1007/s12325-016-0301-1. Epub 2016 Feb 17. Adv Ther. 2016. PMID: 26886776 Free PMC article. Clinical Trial.

Cite

Share

6

Cite

Share

Assessing switchability for biosimilar products: modelling approaches applied to children's growth.

Belleli R, Fisch R, Renard D, Woehling H, Gsteiger S. Belleli R, et al. Among authors: woehling h. Pharm Stat. 2015 Jul-Aug;14(4):341-9. doi: 10.1002/pst.1691. Epub 2015 May 19. Pharm Stat. 2015. PMID: 25989222

Cite

Share

7

Cite

Share

Longitudinal assessment of the impact of multiple switches between a biosimilar and its reference product on efficacy parameters.

Mielke J, Woehling H, Jones B. Mielke J, et al. Among authors: woehling h. Pharm Stat. 2018 May;17(3):231-247. doi: 10.1002/pst.1849. Epub 2018 Feb 8. Pharm Stat. 2018. PMID: 29424120

Cite

Share

8

Cite

Share

GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes.

von Richter O, Skerjanec A, Afonso M, Sanguino Heinrich S, Poetzl J, Woehling H, Velinova M, Koch A, Kollins D, Macke L, Wuerth G. von Richter O, et al. Among authors: woehling h. Br J Clin Pharmacol. 2017 Apr;83(4):732-741. doi: 10.1111/bcp.13170. Epub 2016 Dec 16. Br J Clin Pharmacol. 2017. PMID: 27790726 Free PMC article. Clinical Trial.

Cite

Share

9

Cite

Share

The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.

Griffiths CEM, Thaçi D, Gerdes S, Arenberger P, Pulka G, Kingo K, Weglowska J; EGALITY study group, Hattebuhr N, Poetzl J, Woehling H, Wuerth G, Afonso M. Griffiths CEM, et al. Among authors: woehling h. Br J Dermatol. 2017 Apr;176(4):928-938. doi: 10.1111/bjd.15152. Epub 2017 Mar 1. Br J Dermatol. 2017. PMID: 27787890 Clinical Trial.

Cite

Share

10

Cite

Share

Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin.

Mueller SC, Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl EM, Sievers H, Frank B, Riethling AK, Drewelow B. Mueller SC, et al. Among authors: woehling h. Clin Pharmacol Ther. 2004 Jun;75(6):546-57. doi: 10.1016/j.clpt.2004.01.014. Clin Pharmacol Ther. 2004. PMID: 15179409 Clinical Trial.

Cite

Share